Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 and the cardiovascular system

(2020) Ying-Ying Zheng et al.   Nature Reviews Cardiology

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019

(2020) Sara Tedeschi et al.   CLINICAL INFECTIOUS DISEASES

Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence

(2020) Gabriela M Kuster et al.   EUROPEAN HEART JOURNAL

SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?

(2020) Gabriela M Kuster et al.   EUROPEAN HEART JOURNAL

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

(2020) Francisco J de Abajo et al.   LANCET

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

(2020) Giuseppe Mancia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

(2020) Harmony R. Reynolds et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

(2020) Mandeep R. Mehra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

(2020) Muthiah Vaduganathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

(2020) Chirag Bavishi et al.   JAMA Cardiology

Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19)

(2020) Laine E. Thomas et al.   JAMA Cardiology

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

(2020) Neil Mehta et al.   JAMA Cardiology

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

(2020) Tao Guo et al.   JAMA Cardiology

Response by Zhang et al to Letter Regarding Article, “Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19”

(2020) Peng Zhang et al.   CIRCULATION RESEARCH

Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens

(2020) Francesca Bravi et al.   PLoS One

Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis

(2019) Roberto Manfredini et al.   Journal of Clinical Medicine

Investigation of bias in meta-analyses due to selective inclusion of trial effect estimates: empirical study

(2016) Matthew J Page et al.   BMJ Open

Generic versus brand-name drugs used in cardiovascular diseases

(2015) Lamberto Manzoli et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY